Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors
Sponsor: AstraZeneca
Listed as NCT03983954, this PHASE1 trial focuses on Bladder Cancer and Cervical Squamous Cell Carcinoma and remains ongoing. Sponsored by AstraZeneca, it has been updated 15 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2025 — Dec 2025 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 10 earlier versions
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1
-
Oct 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Oct 2022 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Jul 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Nov 2019 — Nov 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- NeoTX Therapeutics Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .